Cargando…

A case of sarcoidosis‐like reaction associated with immune checkpoint inhibitors in metastatic renal cell carcinoma

INTRODUCTION: Immune checkpoint inhibitors are one of the standard treatments for metastatic renal cell carcinoma. Among immune‐related adverse events, the sarcoidosis‐like reaction is frequently difficult to differentiate from cancer progression. CASE PRESENTATION: A 58‐year‐old man with renal cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katagiri, Akiyoshi, Yamazaki, Hiroyuki, Ikeda, Taro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720716/ https://www.ncbi.nlm.nih.gov/pubmed/35005460 http://dx.doi.org/10.1002/iju5.12372

Ejemplares similares

Editorial Comment to A case of sarcoidosis‐like reaction associated with immune checkpoint inhibitors in metastatic renal cell carcinoma
por: Kijima, Toshiki
Publicado: (2021)

Immune Checkpoint Inhibitor–Associated Sarcoidosis Reaction in the Kidney: Case Report
por: Charkviani, Mariam, et al.
Publicado: (2023)

Suspected immune checkpoint inhibitor‐induced pulmonary sarcoid reaction in metastatic renal cell carcinoma
por: Purcell, Victoria, et al.
Publicado: (2022)

Sarcoidosis-like reaction induced by immune checkpoint inhibitor in a patient with hepatocellular carcinoma: a case report
por: Torres-Zurita, Alberto, et al.
Publicado: (2023)

Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report
por: Sagawa, Tamotsu, et al.
Publicado: (2023)

Concomitant Radioembolization and Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma
por: Adashek, Jacob J., et al.
Publicado: (2018)

Atezolizumab-Induced Sarcoidosis-Like Reaction in a Patient with Metastatic Breast Cancer
por: Tsunoda, Akira, et al.
Publicado: (2022)

Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma
por: Sharma, Revati, et al.
Publicado: (2021)

Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma
por: Zhang, Yumeng, et al.
Publicado: (2022)

Immune checkpoint inhibitors in renal cell carcinoma
por: Ross, Kirsty, et al.
Publicado: (2017)

Systemic sarcoidosis mimicking metastatic renal cell carcinoma with subsequent cardiac involvement
por: Frohlich, Michael, et al.
Publicado: (2020)

Cutaneous sarcoidosis due to immune‐checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitor
por: Pham, J. P., et al.
Publicado: (2021)

Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature
por: Soto, Felipe, et al.
Publicado: (2023)

Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines
por: Resch, I., et al.
Publicado: (2021)

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma
por: Brown, Landon C, et al.
Publicado: (2022)

Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
por: Zaremba, Anne, et al.
Publicado: (2019)

Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor
por: Chiang, Ryan S., et al.
Publicado: (2020)

Whole-Blood Gene Expression Profiles Correlate with Response to Immune Checkpoint Inhibitors in Patients with Metastatic Renal Cell Carcinoma
por: Nagumo, Yoshiyuki, et al.
Publicado: (2022)

Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma
por: Leucht, Katharina, et al.
Publicado: (2022)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Editorial: Immune checkpoint inhibitors in renal cell carcinoma
por: Tykodi, Scott S., et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma
por: Martin, Spencer D., et al.
Publicado: (2023)

Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Martini, Dylan J., et al.
Publicado: (2019)

Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials
por: Zhuang, Tony Zibo, et al.
Publicado: (2022)

Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Lee, Ji Hyun, et al.
Publicado: (2023)

RF30 | PSAT177 A Case of Hypercalcemia Related to Immune Checkpoint Inhibitor-Induced Sarcoidosis-like Granuloma
por: Donangelo, Ines, et al.
Publicado: (2022)

Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
por: Brown, Jacqueline T, et al.
Publicado: (2021)

Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Zhuang, Tony Z, et al.
Publicado: (2022)

Renal Sarcoidosis-like Reaction Induced by PD-1 Inhibitor Treatment in Non-Small Cell Lung Cancer: A Case Report and Literature Review
por: Park, Sang-Don, et al.
Publicado: (2023)

Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Paderi, Agnese, et al.
Publicado: (2021)

Bell's palsy during rechallenge of immune checkpoint inhibitor
por: Takemura, Kohji, et al.
Publicado: (2023)

Feasibility of robotic-assisted partial nephrectomy for complete remission of metastatic renal cell carcinoma after long exposure to immune checkpoint inhibitors (UroCCR-106)
por: Mebroukine, Samy, et al.
Publicado: (2022)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kwok, Christopher, et al.
Publicado: (2023)

Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma
por: Patel, Viral, et al.
Publicado: (2020)

Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study
por: Guillaume, Zoé, et al.
Publicado: (2022)

Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma
por: Koh, Yoko, et al.
Publicado: (2022)

A novel nomogram and prognostic factor for metastatic renal cell carcinoma survival in the era of immune checkpoint inhibitors (ICIs)
por: Alradhi, Mohammed, et al.
Publicado: (2023)

Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors
por: Nuzzo, Pier Vitale, et al.
Publicado: (2020)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
por: Bersanelli, Melissa, et al.
Publicado: (2023)

Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma
por: Abou Alaiwi, Sarah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dfeig4srplso08oh2gu3gecm1a